Structural Genomics Consortium, CHDI Launch Open-access Huntington's Disease Initiative | GenomeWeb

NEW YORK (GenomeWeb) – The Structural Genomics Consortium and the CHDI Foundation have struck an agreement to discover and characterize new drug targets for Huntington's disease and to make their findings available for use by academic researchers and pharmaceutical and biotechnology companies.

Neither the SGC nor CHDI will file for patents on any of their research findings, but will make all the reagents and knowledge they generate widely available without restrictions, the partners said yesterday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.